# LAG-3–associated CD8+ T-cell dysfunction in the cervical cancer tumor microenvironment

**Authors:** Guang Zhang, Lei Wang, Jianhuan Chen, Jing Wang, Abidan Ainiwaer, Cailing Ma

PMC · DOI: 10.3389/fimmu.2026.1750726 · 2026-01-28

## TL;DR

This study shows that LAG-3 is highly expressed in cervical cancer and may weaken CD8+ T cells, helping the cancer progress.

## Contribution

The study reveals a novel role of LAG-3 in suppressing CD8+ T cell function and differentiation in cervical cancer.

## Key findings

- LAG-3 expression increases with cervical cancer progression and is linked to poor clinical features.
- LAG-3 inhibits CD8+ T cell markers like Ki67, T-bet, TNF-α, IFN-γ, and IL-2 in mouse models.
- LAG-3 blocks the differentiation of CD8+ T cells into anti-tumor effector memory T cells.

## Abstract

Cytotoxic T lymphocytes (CTLs, mainly CD8+ T cells) are the primary killer cells in the tumor microenvironment (TME). This study investigates the expression of LAG-3 in the TME of cervical cancer and its regulatory role in CD8+ T cell function.

Cervical tissue pathological sections and fresh cervical tissues were collected from patients with cervical cancer, patients with high-grade squamous intraepithelial lesion (HSIL), and patients who underwent hysterectomy for non-cervical diseases (without a history of other tumors). Immunohistochemistry, Western blotting, quantitative real-time PCR, and fluorescence imaging techniques were used to analyze the expression of LAG-3 in the cervical cancer TME and its correlation with clinical tumor stage, differentiation grade, lymph node metastasis status, and lymphovascular space invasion. A cell co-culture system and a cervical cancer mouse model were established to evaluate the effects of lag-3 on tumor growth and changes in CD8+ T cell function.

LAG-3 is highly expressed in the tumor microenvironment (TME) of cervical cancer, with its expression level increasing as the tumor stage progresses: the lower the degree of differentiation, the higher the LAG-3 expression; LAG-3 expression is also elevated in cases with lymph node metastasis and lymphovascular space invasion. In vivo mouse models confirmed that lag-3 inhibits CD8+ T cells from expressing Ki67, T-bet, TNF-α, IFN-γ, and IL-2. Furthermore, we found that lag-3 not only suppresses the differentiation of naive CD8+ T cells into central memory T cells (TCM) but also inhibits the differentiation of TCM into effector memory T cells (TEM), a subset with stronger anti-tumor effector functions. A similar phenomenon was observed in cell co-culture experiments.

We confirmed that LAG-3 is highly expressed in cervical cancer tissues and is closely correlated with clinical stage, differentiation grade, lymph node metastasis, and lymphovascular space invasion. LAG-3 may inhibit the function of CD8+ T cells in the cervical cancer TME, thereby promoting the progression of cervical cancer.

## Linked entities

- **Genes:** LAG3 (lymphocyte activating 3) [NCBI Gene 3902], Mki67 (antigen identified by monoclonal antibody Ki 67) [NCBI Gene 17345], TBX21 (T-box transcription factor 21) [NCBI Gene 30009], TNF (tumor necrosis factor) [NCBI Gene 7124], IFNG (interferon gamma) [NCBI Gene 3458], IL2 (interleukin 2) [NCBI Gene 3558]
- **Diseases:** cervical cancer (MONDO:0002974)

## Full-text entities

- **Genes:** TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, TBX21 (T-box transcription factor 21) [NCBI Gene 30009] {aka IMD88, T-PET, T-bet, TBET, TBLYM}, IL2 (interleukin 2) [NCBI Gene 3558] {aka IL-2, TCGF, lymphokine}, LAG3 (lymphocyte activating 3) [NCBI Gene 3902] {aka CD223}
- **Diseases:** cervical diseases (MESH:D002575), cervical cancer (MESH:D002583), tumor (MESH:D009369), HSIL (MESH:D000081483), lymph node metastasis (MESH:D008207)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12891123/full.md

---
Source: https://tomesphere.com/paper/PMC12891123